- Home
- CHYM vs HALO Comparison
CHYM vs HALO Comparison
Compare CHYM & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$65.33
Company Overview
Basic Information| Metric | CHYM | HALO |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 8.8B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | CHYM | HALO |
|---|---|---|
| Price | $19.67 | $65.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | $32.88 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 3.7M | 1.7M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.56 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $23.29 | $28.24 |
| Revenue Next Year | $18.40 | $12.79 |
| P/E Ratio | ★ N/A | $25.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.17 | $47.50 |
| 52 Week High | $38.67 | $82.22 |
Technical Indicators
Market Signals| Indicator | CHYM | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 35.45 |
| Support Level | $19.46 | $63.85 |
| Resistance Level | $21.68 | $65.40 |
| Average True Range (ATR) | 1.54 | 1.87 |
| MACD | -0.14 | -0.50 |
| Stochastic Oscillator | 0.80 | 22.80 |
Price Performance
Historical Comparison CHYM
HALO
About CHYM Chime Financial Inc.
Chime Financial Inc is a financial technology company that believes in core banking services.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.